- Home
- NERV vs NXDT Comparison
NERV vs NXDT Comparison
Compare NERV & NXDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NERV | NXDT |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.6M | 229.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | NERV | NXDT |
|---|---|---|
| Price | $7.85 | $4.43 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 160.1K | 143.2K |
| Earning Date | 07-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.99 |
| Revenue | ★ $41,175,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $2.55 |
| 52 Week High | $12.46 | $5.26 |
Technical Indicators
Market Signals| Indicator | NERV | NXDT |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 43.10 |
| Support Level | $5.34 | $4.35 |
| Resistance Level | $12.46 | $5.04 |
| Average True Range (ATR) | 0.65 | 0.27 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 79.94 | 0.00 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.